Third mRNA COVID-19 Vaccine Dose Appears to Be Safe

FRIDAY, April 15, 2022 (HealthDay News) -- The third dose of the COVID-19 mRNA vaccine is safe, according to a study published online April 14 in JAMA Network Open.
Michiel J.M. Niesen, Ph.D., from nference in Cambridge, Massachusetts, and colleagues evaluated the safety of third-dose vaccination with U.S. Food and Drug Administration–approved COVID-19 mRNA vaccines. Electronic health record data (December 2020 to October 2021) were used to identify 47,999 individuals receiving three-dose COVID-19 mRNA vaccines.
The researchers found that reporting of severe adverse events remained low after the third vaccine dose, with rates of pericarditis (0.01 percent), anaphylaxis (0 percent), myocarditis (0 percent), and cerebral venous sinus thrombosis (no individuals) consistent with results from earlier studies. Compared to the second dose, significantly more individuals reported low-severity adverse events after the third dose, including fatigue, lymphadenopathy, nausea, headache, arthralgia, myalgia, diarrhea, fever, vomiting, and chills.
"This study provides further evidence suggesting that third-dose vaccination with the same type of COVID-19 mRNA vaccine as used in the primary series is associated with safe outcomes in eligible populations," the authors write. "Together with previous studies of the safety and effectiveness associated with booster doses, our study suggests that third-dose mRNA COVID-19 vaccination may be appropriate for at-risk populations."
Two authors disclosed financial ties to pharmaceutical companies, including Pfizer and Moderna.
Related Posts
“Atlas de células cerebrales humanas” brinda nuevas perspectivas sobre la salud y las enfermedades cerebrales
VIERNES, 13 de octubre de 2023 (HealthDay News) -- Después de un esfuerzo...
Heart Inflammation Very Rare After COVID Vaccination
TUESDAY, April 19, 2022 (HealthDay News) -- The heart inflammation that followed...
Resistant Starch Provides Lasting Benefit in Lynch Syndrome
THURSDAY, Aug. 18, 2022 (HealthDay News) -- For patients with Lynch syndrome...
Lenvatinib + Pembrolizumab Treats Advanced Endometrial Cancer
MONDAY, Jan. 31, 2022 (HealthDay News) -- For patients with advanced endometrial...